Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary

被引：0
|
作者：
Zoltán Vokó
László Nagyjánosi
Zoltán Kaló
机构：
[1] Eötvös Loránd University,Department of Health Policy & Health Economics, Institute of Economics, Faculty of Social Sciences
[2] Syreon Research Institute,undefined
[3] National Institute for Health Development,undefined
来源：
BMC Public Health | / 12卷
关键词：
Cervical cancer; Human papillomavirus; Vaccine; Cervarix; Hungary; Cost-effectiveness;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF HUMAN PAPILLOMAVIRUS VACCINE FOR PREVENTION OF CERVICAL CANCER IN TAIWAN
    Liu, P. H.
    Wang, J. D.
    VALUE IN HEALTH, 2009, 12 (03) : A46 - A46
  • [42] Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine
    Goldie, SJ
    Kohli, M
    Grima, D
    Weinstein, MC
    Wright, TC
    Bosch, FX
    Franco, E
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (08): : 604 - 615
  • [43] Cost-effectiveness of human papillomavirus vaccination and screening in Spain
    Diaz, Mireia
    de Sanjose, Silvia
    Ortendahl, Jesse
    O'Shea, Meredith
    Goldie, Sue J.
    Bosch, F. Xavier
    Kim, Jane J.
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (16) : 2973 - 2985
  • [44] AS04-Adjuvanted Human Papillomavirus (HPV) Types 16 and 18 Vaccine (Cervarix®) A Review of its Use in the Prevention of Premalignant Cervical Lesions and Cervical Cancer Causally Related to Certain Oncogenic HPV Types
    McKeage, Kate
    Romanowski, Barbara
    DRUGS, 2011, 71 (04) : 465 - 488
  • [45] Modeling Cost-Effectiveness of Cervical Cancer Screening in Hungary
    Voko, Zoltan
    Nagyjanosi, Laszlo
    Margitai, Barnabas
    Koevi, Rita
    Toth, Zoltan
    Laszlo, Daniel
    Kalo, Zoltan
    VALUE IN HEALTH, 2012, 15 (01) : 39 - 45
  • [46] AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): A review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types
    McKeage K.
    Romanowski B.
    Drugs, 2011, 71 (4) : 465 - 488
  • [47] HPV-16/18 AS04-adjuvanted vaccine prevented cervical intraepithelial neoplasia ≥ grade 3 in young women
    Budenholzer, Brian
    ANNALS OF INTERNAL MEDICINE, 2012, 157 (02)
  • [48] Cost-effectiveness analysis of the implementation of a quadrivalent (6,11,16,18 types) human papillomavirus vaccine to the existing Belgian cervical cancer screening programme
    Annemans, L.
    Remy, V
    Largeron, N.
    VALUE IN HEALTH, 2007, 10 (06) : A442 - A443
  • [49] Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-Adjuvanted Cervical Cancer Vaccine Coadministered With Combined Diphtheria-Tetanus-Acellular Pertussis-inactivated Poliovirus Vaccine to Girls and Young Women
    Garcia-Sicilia, Jose
    Schwarz, Tino F.
    Carmona, Alfonso
    Peters, Klaus
    Malkin, Jean-Elie
    Tran, Phu M.
    Behre, Ulrich
    Iturbe, Enrique B.
    Catteau, Gregory
    Thomas, Florence
    Dobbelaere, Kurt
    Descamps, Dominique
    Dubin, Gary
    JOURNAL OF ADOLESCENT HEALTH, 2010, 46 (02) : 142 - 151
  • [50] Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China
    Liu, Yi-Jun
    Zhang, Qian
    Hu, Shang-Ying
    Zhao, Fang-Hui
    BMC CANCER, 2016, 16
12345